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antiplatelet therapy, inpatient and outpatient treatment of
ischemic stroke, MI, and bleeds, and long-term care for
patients with disability. We examined the cost-effective-
ness of clopidogrel for subgroups of patients deﬁned on
the basis of age at therapy initiation (55, 65, and 75 years)
and gender. Cost-effectiveness was assessed using the
ratio of the difference (clopidogrel minus aspirin) in
expected lifetime medical-care costs to the corresponding
difference in life expectancy. A 3% discount rate was
used. RESULTS: One hundred patients with recent IS,
recent MI, or PAD receiving clopidogrel would experience
4.5–6.3 fewer atherothrombotic events and 3.6–8.7 
fewer bleeds over their lifetimes in comparison with 100
patients receiving aspirin. The expected gain in life-years
ranges from 0.33–0.69 per patient. Expected total life-
time medical-care costs are $9,222–$16,850 higher for 
clopidogrel patients. Cost-effectiveness of clopidogrel
ranges from $40,204–$49,107 per life-year saved, and is
sensitive to the assumed risk reduction for clopidogrel.
CONCLUSION: Clopidogrel is cost-effective versus
aspirin in patients with recent IS, recent MI, or PAD.
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OBJECTIVE: This retrospective, observational, health
plan administrative claims database study examined
treatment patterns, resource utilization, and costs of
venous thromboembolic (VTE) disease [deep venous
thrombosis (DVT) and pulmonary embolism (PE)] in a
managed care setting. METHODS: Medical and phar-
macy claims of patients with a newly diagnosed VTE
event were gathered from 2 US health plan databases
from January 1997 through September 2001. Inclusion
criteria included a VTE event between January 1, 1998
and December 31, 2000 (no VTE diagnosis or anti-
coagulation therapy 3 months prior to index VTE event),
continuous health plan enrollment 6 months prior and 12
months after index VTE event, and a VTE medication ﬁll
after index date. Medical and pharmacy care associated
with recurrent VTE or bleeding events were based on each
patient’s index VTE event, and detailed by type, number,
and cost. Costs of recurrent episodes were calculated
using general linear model regression and bootstrap tech-
niques. RESULTS: A total of 2147 patients (DVT = 1499;
PE = 373; DVT&PE = 275) were enrolled (mean age =
61.6 ± 15.9 years, 46.3% male). Median pre- and post-
index observation times were 17.1 and 19.2 months,
respectively. Mean total medical costs for DVT, PE, and
DVT&PE during the index VTE episode were $2293,
$7157, and $3963, respectively. Warfarin treatment was
administered for a mean 6.3 months at an average cost
of $145. The annualized rates and adjusted costs of post-
index VTE events were 9.48% and $5331, respectively,
for VTE episodes; and 5.52% and $8978, respectively, 
for bleeding episodes. The rate of recurrent VTE episodes
was signiﬁcantly lower in the DVT group than in the PE
group, and the cost of post-index bleed episodes was 
signiﬁcantly higher in the PE group. No other recurrent
rates or cost differences were signiﬁcant. CONCLU-
SIONS: Current therapy for VTE patients is associated
with high costs and signiﬁcant recurrent and adverse
events. Approaches to therapy that increase effectiveness
and decrease risk are needed.
MENTAL HEALTH
MH1
GENDER VARIATION IN QUALITY OF
PHARMACOLOGIC CARE OF CHILDREN
DIAGNOSED WITH
ATTENTIONDEFICIT/HYPERACTIVITY
DISORDER (ADHD)
Sarawate CA1, Hankin C2
1University of Illinois at Chicago, Chicago, IL, USA; 2McNeil
Consumer and Specialty Pharmaceuticals, Fort Washington,
PA, USA
Gender variation in diagnosis and treatment of ADHD is
well documented: boys are more likely to be diagnosed
and receive pharmacologic treatment than girls. However,
little is known about gender variation in the quality
(dosage and persistence) of pharmacologic treatment
received by ADHD-diagnosed children. OBJECTIVE: To
examine gender variation in intensity and persistence of
psychostimulant treatment among a national, population-
based sample of ADHD-diagnosed children. METHODS:
We analyzed medical and pharmaceutical claims in the
Medical Expenditures Panel Survey (MEPS) from January
1 through December 31, 1998 among all ADHD-diag-
nosed children (N = 195) aged 4–19 years. Psychostimu-
lant doses were converted to Methylphenidate Equivalent
Units (MEU) according to previously published research
(MEU: 20mg Methylphenidate = 10mg dextroampheta-
mine = 10mg amphetamine salts = 56.25mg Pemoline).
Doses were classiﬁed as high (>15.0mg MEU), medium
(5.0–15.0mg MEU), or low (<5.0mg MEU). Persistence
of treatment was determined by number of prescription
ﬁlls (PF) in a calendar year. Separate weighted logistic and
multiple regression analyses were conducted with MEU
and PF as dependent variables respectively. RESULTS: As
has been reported previously in the literature, males were
1.3 (+/-0.004) times more likely to receive a prescription
for psychostimulants (p < 0.001). However, among 
those receiving any psychostimulant, females were 1.2
(+/-0.008) times more likely than males to receive high
doses (p < 0.001). There was no difference in persistence
of psychostimulant treatment by gender. CONCLUSION:
Whereas girls with AD/HD were less likely to be treated
with psychostimulants, once treated, they received higher
